Other languages Wave Life Sciences Ltd.

Equities

WVE

SG9999014716

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
6.14 ^USD	+4.42%		+31.76%	+21.58%

Apr. 30	Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency	CI
Apr. 23	Wave Life Sciences Ltd. Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency	Apr. 30
Wave Life Sciences Ltd. Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	Apr. 23
Sector Update: Health Care Stocks Higher Late Afternoon	Mar. 06
WAVE Life Sciences Shares Surge After Q4 Beats Estimates	Mar. 06
Wave Life Sciences Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06
Wave Life Sciences Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06
Wave Life Sciences Starts Dosing in Neuromuscular Disorder Study	Dec. 15
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	Dec. 15
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Dec. 07
Sector Update: Health Care	Dec. 07
Investor Sentiment Muted Ahead of November Jobs Report, Driving Quiet Premarket Action for US Equity Futures	Dec. 07
Top Premarket Decliners	Dec. 07
WAVE Life Sciences Kicks off $100 Million Offering; Shares Plunge in Premarket Activity	Dec. 07
Wave Life Sciences Ltd. Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency	Dec. 06
Wave Life Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
WAVE Life Sciences Submits First Clinical Trial Application for RNA Editing Candidate	23-09-06
Wave Life Sciences Ltd. Announces Submission of First Clinical Trial Application for Wve-006	23-09-05
Wave Life Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
WAVE Life Sciences' Study of WVE-004 to Treat ALS, Dementia Shows No Evidence of Benefits; Shares Tumble 27% Pre-Bell	23-05-23
Wave Life Sciences Announces Topline Results from Phase 1B/2A Focus-C9 Study of WVE-004 for C9orf72-Associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia	23-05-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Wave Life Sciences Ltd.

Equities

WVE

SG9999014716

Other languages

Filters